drugset / Trial / NCT00772681

Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma

NCT00772681

Phase 4 Completed 57 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

* To assess the efficacy of docetaxel, cisplatin combination in terms of disease free survival. * Time to progression of the disease in terms of local and distant failure; assess the survival time, and assess the objective (clinical and radiological) response rate and the safety of the treatment.

Timeline

Start
2004-10
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 100 mg/m2
Subject Docetaxel Small molecule 75 mg/m2